Lamisil Solution, 1%
Company: Novartis
Approval Status: Approved March 2001
Treatment for: Dermatologic infections
Areas: Dermatology/Plastic Surgery
Possible similar drugs: Lamisil; Lamisil
| General Information | Clinical Results | Side Effects | Mechanism of Action | Additional Information |
General Information
Lamisil Solution, 1% is a synthetic antifungal compound approved for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur, and tinea pedis (athlete's foot), tinea cruris (jock itch), or tinea corporis (ringworm), due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermaphyton floccosum.
Lamisil Solution, 1% is designed for one week usage and is administered to the infected area once or twice daily, depending on indication.
Clinical Results
The effectiveness of Lamisil Solution, 1% was evaluated in separate eight week placebo-controlled trials for tinea (pityriasis) versicolor, tinea pedis, and tinea corporis/cruris, involving a total of 898 subjects. In the majority of pateints, relief of symptoms began within the one week treatment period and continued improvement was recorded over the following seven weeks. (from Lamisil Solution, 1% Prescribing Information)
Side Effects
Adverse events associated with the use of terbinafine hydrochloride may include (but are not limited to) the following:
- site irritation
- itching
- skin exfoliation
- erythematous rash
Mechanism of Action
Lamisil Solution, 1% (terbinafine hydrochloride solution) is a synthetic allyamine derivative. Terbinafine hydrochloride is thought to act by inhibiting the epoxidation of squalene, thus blocking the biosysnthesis of ergosterol, an essential component of fungal cell membranes. Depending on the concentration of the drug and the fungal species being tested in vitro, terbinafine hydrochloride may be fungicidal. (from Lamisil Solution, 1% Prescribing Information)
Additional Information
For additional information on Lamisil Solution, 1%, please visit Novartis.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
